Knight Therapeutics Inc. (TSX:GUD)
10.83
+0.10 (0.93%)
Oct 9, 2026, 4:00 PM EST
Knight Therapeutics Employees
Knight Therapeutics had 830 employees as of December 31, 2025. The number of employees increased by 85 or 11.41% compared to the previous year. That makes Knight Therapeutics the 16,279th largest employer in the world and 259th in Canada.
Employees
830
Change (1Y)
85
Growth (1Y)
11.41%
Revenue / Employee
659.40K CAD
Profits / Employee
17.92K CAD
Market Cap
1.06B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 830 | 85 | 11.41% | 830 | 0 |
| Dec 31, 2024 | 745 | 20 | 2.76% | 745 | 0 |
| Dec 31, 2023 | 725 | 27 | 3.87% | 725 | 0 |
| Dec 31, 2022 | 698 | 38 | 5.76% | 698 | 0 |
| Dec 31, 2021 | 660 | -19 | -2.80% | 660 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| Verano Holdings | 3,800 |
| Cresco Labs | 2,900 |
| Canopy Growth | 1,128 |
| Aurora Cannabis | 1,028 |
| Vireo Growth | 612 |
| Cronos Group | 610 |
Knight Therapeutics News
- 4 days ago - Knight Therapeutics Announces Launch of TAVALISSE® in Brazil - BNN Bloomberg
- 4 days ago - Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil - Financial Post
- 11 days ago - Kyowa Kirin, Knight Therapeutics Enter Distribution Deal For POTELIGEO In Latin America - Nasdaq
- 11 days ago - Knight Therapeutics, Kyowa Kirin enter distribution agreement for POTELIGEO - TheFly
- 11 days ago - Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America - Business Wire
- 11 days ago - Knight Therapeutics signs exclusive distribution agreement with Kyowa Kirin - TheFly
- 11 days ago - Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab) - GlobeNewsWire
- 15 days ago - Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada’s Top Growing Companies - Financial Post